Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 97,428 | 160,203 | 11,639 | 12,381 | 7,041 |
| Marketable Securities | 102,791 | 7,133 | 4,340 | 0 | 10,000 |
| Receivables | 6,170 | 12,634 | 6,551 | 8,916 | 12,307 |
| Inventories | 1,633 | 269 | 1,392 | 1,697 | 1,301 |
| Income taxes - deferred | N/A | N/A | N/A | N/A | 237 |
| Other current assets | 6,690 | 4,919 | 959 | 829 | 1,344 |
| TOTAL | $214,712 | $185,158 | $24,881 | $23,823 | $32,230 |
| Non-Current Assets | |||||
| PPE Net | 372 | 486 | 867 | 788 | 455 |
| Investments And Advances | 29,728 | 0 | 0 | 0 | 1,341 |
| Intangibles | 69,139 | 67,529 | 69,908 | 68,150 | 70,564 |
| Other Non-Current Assets | 189,110 | 4,856 | 9,057 | 11,499 | 15,993 |
| TOTAL | $288,349 | $72,871 | $79,832 | $80,437 | $88,353 |
| Total Assets | $503,061 | $258,029 | $104,713 | $104,260 | $120,583 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 201,985 | N/A | N/A | N/A | 10,000 |
| Accounts payable and accrued liabilities | 4,083 | 7,698 | 8,280 | 10,181 | 17,262 |
| Accrued Expenses | 5,405 | 4,866 | 5,337 | 4,961 | 11,933 |
| Other current liabilities | 10,414 | 7,859 | 1,712 | 356 | N/A |
| TOTAL | $222,821 | $22,779 | $28,939 | $35,439 | $43,643 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 195,908 | N/A | 13,443 | 20,286 |
| Deferred Revenues | N/A | N/A | 116 | 486 | 1,240 |
| Other Non-Current Liabilities | 45,338 | 10,255 | 19,907 | 19,836 | 34,406 |
| TOTAL | $42,958 | $210,842 | $26,161 | $42,336 | $68,755 |
| Total Liabilities | $265,779 | $233,621 | $55,100 | $77,775 | $112,398 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 20,773 | 19,578 | 20,615 | 20,208 | 19,683 |
| Common Shares | 20 | 20 | 21 | 21 | 21 |
| Retained earnings | -429,491 | -659,315 | -671,339 | -682,759 | -682,232 |
| Other shareholders' equity | 4,903 | 3,043 | 2,914 | -280 | -280 |
| TOTAL | $237,282 | $24,408 | $49,613 | $26,485 | $8,185 |
| Total Liabilities And Equity | $503,061 | $258,029 | $104,713 | $104,260 | $120,583 |